Company news: Pfizer lupus collaboration; pharmacists want pharmas' help with patient support

Share this article:
Pfizer's Centers for Therapeutic Innovation is partnering with Alliance for Lupus Research to fund novel translational research projects through academic medical centers. ALR and CTI hope to find new therapies for lupus through the work of joint project teams made up of Pfizer scientists and academic researchers. The collaboration “represents an evolution of the R&D ecosystem,” said Pfizer, “in which industry works in close partnership with academia, non-profit organizations and other stakeholders to advance research and benefit patients.” Lupus, a chronic autoimmune disease, affects as many as 1.5 million Americans, mostly women in their childbearing years.

Pharmacists want drug companies to provide them with online access to resources for patient support, a Manhattan Research survey found. The firm surveyed 752 US pharmacists and found that more than three-quarters want access to online patient education materials and 64% of retail pharmacists want patient assistance or vouchers from companies through their electronic health records systems. Around two-fifths of pharmacists report spending more time on care and support of patients, including directing them to pharma company websites and apps, than they did two years ago, with top conditions being diabetes, cardiovascular disorders, pain, respiratory distress and psychosis/depression, in that order.
Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.